Article
Nutrition & Dietetics
Wuli Tang, Gang Xie, Junlin Li, Wei Tan, Rongqi Yi, Ling Yang, Lingqin Zhang, Jiaxing Deng, Yue Zhang, Kang Li
Summary: This study investigated the relationship between body composition parameters and disease severity in Crohn's disease (CD) patients treated with infliximab (IFX). The results showed significant differences in subcutaneous adiposity index (SAI), visceral adiposity index (VAI), and skeletal muscle mass index (SMI) among patients with different disease activity statuses. SMI was identified as a reliable indicator of disease activity status.
FRONTIERS IN NUTRITION
(2023)
Article
Biochemistry & Molecular Biology
Yiyoung Kwon, Eun-Sil Kim, Yoon-Zi Kim, Yon-Ho Choe, Mi-Jin Kim
Summary: This study aims to measure the concentration of cytokines produced during the inflammation process to investigate if there are any differences in response to treatment of pediatric Crohn's disease and to determine if the initial tumor necrosis factor-alpha (TNF-alpha) level affected the trough concentration of infliximab (IFX).
Article
Radiology, Nuclear Medicine & Medical Imaging
Chao Zhu, Jing Hu, Xia Wang, Cuiping Li, Yankun Gao, Jianying Li, Yaqiong Ge, Xingwang Wu
Summary: This study suggests that a CTE-based radiomics model has potential value in predicting mucosal healing in CD patients. A nomogram constructed by combining radiomics signatures and clinical features can help clinicians select appropriate therapeutic strategies for CD patients.
EUROPEAN RADIOLOGY
(2022)
Article
Immunology
Li Li, Rirong Chen, Yingfan Zhang, Gaoshi Zhou, Baili Chen, Zhirong Zeng, Minhu Chen, Shenghong Zhang
Summary: MMP3, CCL2, and CRP are promising biomarkers for predicting PNR to infliximab. A PNR classifier combining these three indicators can accurately predict PNR and may be useful in clinical practice for therapy selection.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chen Yueying, Feng Jing, Feng Qi, Shen Jun
Summary: A magnetic resonance enterography-based model was constructed in this study to predict the risk of loss of response to infliximab (IFX) in bio-naive patients with Crohn's disease (CD), providing an effective tool for the early estimation of treatment response before biological intervention.
EUROPEAN RADIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Wan-Ting Cao, Rong Huang, Shan Liu, Yi-Hong Fan, Mao-Sheng Xu, Yi Xu, Hui Ni
Summary: This study aimed to explore the predictive value of infliximab trough level (ITL) in combination with inflammatory biomarkers on long-term endoscopic outcomes in Crohn's disease (CD) patients during infliximab (IFX) maintenance therapy. The results showed that low ITL and high inflammatory biomarker levels increased the risk of endoscopic activity at different stages of treatment. The combination of ITL and inflammatory biomarkers can moderately predict endoscopic activity. Furthermore, ITL was also associated with endoscopic relapse-free survival.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Eun Sil Kim, Sujin Choi, So Yoon Choi, Ji Hyung Park, Byung-Ho Choe, Soo-Youn Lee, Mi Jin Kim, Yon Ho Choe, Ben Kang
Summary: NUDT15 intermediate metabolisers are associated with lower loss of response in pediatric patients with CD treated with IFX and AZA combination therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Yizhong Wang, Xuefeng Gao, Xinyue Zhang, Fangfei Xiao, Hui Hu, Xiaolu Li, Fang Dong, Mingming Sun, Yongmei Xiao, Ting Ge, Dan Li, Guangjun Yu, Zhanju Liu, Ting Zhang
Summary: The study revealed that pediatric CD patients have gut microbial dysbiosis and altered metabolism after IFX therapy, which is related to treatment outcomes. The effects of IFX treatment may be mediated by enriching bacteria taxa that produce SCFAs and BSH, thereby inhibiting inflammation and restoring bile acid metabolism. Some fecal bacteria and metabolites may serve as predictors of IFX therapy outcomes for pediatric CD patients.
Article
Pharmacology & Pharmacy
Shuyan Li, Yan Ma, Hongling Sun, Zijun Ni, Shurong Hu, Yan Chen, Meijuan Lan
Summary: This study investigated the adherence to Infliximab (IFX) among Chinese Crohn's disease patients and evaluated the association between medication belief and adherence. The results showed that medication concerns may be a predictive factor of adherence, and by enhancing knowledge and relieving concerns, patients' adherence to IFX can be increased.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Immunology
So Yoon Choi, Yiyoung Kwon, Sujin Choi, So Mi Lee, Byung-Ho Choe, Ben Kang
Summary: This study investigated whether infliximab (IFX) trough levels are associated with transmural healing in pediatric patients with Crohn's disease (CD) after 1-year treatment. The results showed that IFX trough levels were associated with endoscopic healing but not with transmural healing in pediatric patients with CD.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Benedicte Caron, Mathurin Fumery, Patrick Netter, Laurent Peyrin-Biroulet
Summary: This article is linked to the papers by Hanzel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Nutrition & Dietetics
Iolanda Cioffi, Filippo Scialo, Olivia Di Vincenzo, Monica Gelzo, Maurizio Marra, Anna Testa, Fabiana Castiglione, Maria Vitale, Fabrizio Pasanisi, Lidia Santarpia
Summary: This study aimed to assess the relationship between inflammation, malnutrition risk, and nutritional status in patients with Crohn's disease. Asymptomatic or untreated inflammation along with malnutrition can impair clinical outcomes in these patients.
Article
Pharmacology & Pharmacy
Beatriz Orts, Ana Gutierrez, Lucia Madero, Laura Sempere, Ruben Frances, Pedro Zapater
Summary: There are differences in the immunological profile and clinical evolution of patients with Crohn's disease according to the anti-TNF dose and serum trough levels.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Chenglin Ye, Sizhe Zhu, Jingping Yuan
Summary: This study analyzed the gene expression profiles of patients with Crohn's disease (CD) and identified two gene subtypes: immune and metabolic. The immune subtype was associated with leukocyte migration and cytokine interactions, while the metabolic subtype was associated with metabolic pathways. The combination of interleukin 1 beta, interleukin 6, and Toll-like receptor 4 effectively distinguished between these two gene subtypes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch
Summary: This post hoc analysis suggests that infliximab and ustekinumab have similar efficacy and speed of onset in biologic-naive patients with CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
